公开(公告)号：EP3801589B1

公开(公告)日：2024-08-28

申请号：EP19809981.4

申请日：2019-05-31

IPC: A61K35/15 ,  A61K38/17 ,  A61P19/08 ,  C12N5/077

CPC classification number: A61P19/08 ,  C12N5/0654 ,  A61K38/1709 ,  A61K2239/3120230501 ,  A61K39/4622 ,  A61K2239/3820230501 ,  C12N5/0645 ,  A61K39/4614 ,  A61K39/464

公开(公告)号：EP2615166B1

公开(公告)日：2018-08-15

申请号：EP11823785.8

申请日：2011-09-07

Applicant: Kang Stem Biotech Co., LTD

Inventor： KANG, Kyung Sun ,  SEO, Min Soo ,  PARK, Sang Bum

IPC: C12N5/074 ,  C12N5/077 ,  A61K35/32 ,  A61P19/00

CPC classification number: C12N5/0655 ,  A61K35/50 ,  C12N5/0605 ,  C12N5/0606 ,  C12N5/0653 ,  C12N5/0654 ,  C12N5/0668

Abstract: The present invention relates to equine amniotic fluid-derived multipotent stem cells (eAF-MSCs) and a preparation method thereof. More particularly, the present invention relates to equine amniotic fluid-derived multipotent stem cells which exhibit all negative immunological characteristics with respect to the human markers, CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P and CD200, and exhibit all positive immunological characteristics with respect to the human markers, CD44, CD90 and CD105, and have the ability to differentiate into ectoderm, mesoderm or endoderm-derived cells. The present invention confirmed that equine amniotic fluid can be a source of equine adult multipotent stem cell supply, and the equine amniotic fluid-derived multipotent stem cells exhibit excellent self-renewal ability and differentiation capability. Therefore, the cells can be used as an active ingredient for cell therapy of horses, which requires a large amount of cells. In particular, the stem cells of the present invention having excellent self-renewal ability and differentiation capability are useful for the treatment of bone, tendon, or muscle injuries and bone loss diseases of racehorses.

公开(公告)号：EP3303556A1

公开(公告)日：2018-04-11

申请号：EP16727156.8

申请日：2016-05-27

Applicant: Katholieke Universiteit Leuven

Inventor： BLOEMEN, Veerle ,  BOLANDER, Johanna ,  LUYTEN, Frank

IPC: C12N5/00 ,  C12N5/077

CPC classification number: A61K35/28 ,  A61P19/02 ,  A61P19/04 ,  A61P19/10 ,  C12N5/0012 ,  C12N5/0037 ,  C12N5/0654 ,  C12N5/0655 ,  C12N2500/25 ,  C12N2500/33 ,  C12N2500/38 ,  C12N2500/46 ,  C12N2500/98 ,  C12N2500/99 ,  C12N2501/155 ,  C12N2501/37 ,  C12N2501/39 ,  C12N2501/395 ,  C12N2506/1392 ,  C12N2513/00 ,  C12N2533/18 ,  C12N2533/54 ,  C12N2533/78

Abstract: The application provides biocompatible carriers comprising bone forming and/or cartilage forming cells and methods for making them. The application further provides pharmaceutical compositions comprising said ATMPs and method of treatments using said ATMPs. The application further relates to said ATMPS for use in the treatment of bone disorders, cartilage disorders and joint disorders. The current invention further relates to method of treatments of bone disorders, cartilage disorders and joint disorders.

公开(公告)号：EP3162387A4

公开(公告)日：2018-01-31

申请号：EP15812617

申请日：2015-06-26

Applicant: KYUNGPOOK NATIONAL UNIV INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： JEONG YOUNG HUN ,  KWAK JONG-YOUNG ,  KIM JEONG HWA ,  KIM CHANG GUN

IPC: A61L27/44 ,  A61L27/18 ,  A61L27/38 ,  A61L27/54 ,  A61L27/56 ,  C12M1/12

CPC classification number: A61L31/125 ,  A61L27/18 ,  A61L27/3821 ,  A61L27/54 ,  A61L27/56 ,  A61L31/146 ,  A61L31/16 ,  A61L2400/12 ,  A61L2430/02 ,  C12M25/14 ,  C12N5/0068 ,  C12N5/0654 ,  C12N2533/30 ,  C12N2535/10 ,  C12N2537/00 ,  C08L67/04

Abstract: Disclosed are a nanofiber mat, a manufacturing method thereof, and applications thereof as a mat for cell culturing or as a barrier membrane for guided bone regeneration (GBR). The nanofiber layer includes a nanofiber layer and a reinforcement pattern that is disposed on the nanofiber layer and adhesively connected with the nanofiber layer. The nanofiber layer and the reinforcement pattern are combined with each other by at least one of the melting-solidification of at least a part of the nanofiber layer together with the reinforcement pattern, the dissolution-solidification of the same, and the penetration of a part of the reinforcement pattern into the nanofiber layer, followed by solidification.

公开(公告)号：EP3064571A4

公开(公告)日：2017-09-06

申请号：EP13896338

申请日：2013-11-05

Applicant: BBHC CO LTD

Inventor： LEE SANG YEON ,  JUNG WON JU ,  KIM HO BIN ,  OH MIN SUN ,  LEE KYE HO

IPC: C12N5/0775 ,  A61K35/30 ,  A61K35/32 ,  A61K35/35 ,  A61K35/407 ,  C12N5/02 ,  C12N5/071 ,  C12N5/074 ,  C12N5/077 ,  C12N5/0793

CPC classification number: C12N5/0654 ,  A61K35/32 ,  C12N5/0696 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2500/76 ,  C12N2501/155 ,  C12N2501/39 ,  C12N2501/999 ,  C12N2506/1369 ,  C12N2506/45

Abstract: The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiation an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell produced by using the medium composition into osteoblasts. When using the medium composition according to the present invention, induced pluripotent stem cells using mesenchymal stem cells can be produced efficiently, and the pluripotent stem cells which have been produced can be useful as a cell treatment agent by being capable of being differentiated into osteoblasts.

Abstract translation: 本发明涉及含有用于诱导多能干细胞去分化的埃克氏菌（Ecklonia cava）提取物的培养基组合物。 此外，本发明涉及使用该培养基组合物制造的诱导性多能干细胞分化成成骨细胞的方法。 在使用本发明的培养基组合物的情况下，可以有效地制造使用了间充质干细胞的诱导性多能干细胞，通过能够分化为成骨细胞，可以将所制作的多能干细胞用作细胞治疗剂。

公开(公告)号：EP3107995A4

公开(公告)日：2017-08-02

申请号：EP15752783

申请日：2015-02-18

Applicant: MASSACHUSETTS INST TECHNOLOGY ,  NAT UNIV SINGAPORE

Inventor： POON ZHIYONG ,  LEE WONG CHENG ,  VAN VLIET KRYSTYN J

IPC: C12N5/0775 ,  C12N5/074

CPC classification number: C12N5/0663 ,  A61K35/28 ,  A61K2035/124 ,  C12N5/0654

Abstract: The invention provides, inter alia, populations of large mesenchymal stem cells (MSC)(as well as conditioned medium from these cells) with enhanced regenerative potential, as well as methods of culturing and using these populations, such as therapeutic methods of mediating tissue repair or enhancing homing and engraftment of hematopoietic stem cells. These large MSC populations can, in certain embodiments, be produced by biophysically sorting an MSC-containing population.

Abstract translation: 本发明尤其提供了具有增强的再生潜能的大间充质干细胞（MSC）群体（以及来自这些细胞的条件培养基），以及培养和使用这些群体的方法，例如介导组织修复的治疗方法 或增强造血干细胞的归巢和植入。 在某些实施方案中，这些大的MSC群体可以通过生物物理学分选含MSC的群体而产生。

公开(公告)号：EP1165830B1

公开(公告)日：2017-07-12

申请号：EP00913860.3

申请日：2000-03-10

Applicant: University of Pittsburgh of the Commonwealth System of Higher Education ,  The Regents of the University of California

Inventor： KATZ, Adam, J. ,  LLULL, Ramon ,  FUTRELL, J., William ,  HEDRICK, Marc, H. ,  BENHAIM, Prosper ,  LORENZ, Hermann, Peter ,  ZHU, Min

IPC: C12N5/077 ,  C12N5/0775

CPC classification number: C12N5/0658 ,  A61K35/12 ,  A61K48/00 ,  C12N5/0068 ,  C12N5/0647 ,  C12N5/0652 ,  C12N5/0653 ,  C12N5/0654 ,  C12N5/0655 ,  C12N5/0667 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2501/01 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2502/1305 ,  C12N2506/1384 ,  C12N2510/00 ,  C12N2533/90

Abstract: The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The invention also provides a method of isolating stem cells from adipose tissues. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

Abstract translation: 本发明提供了脂肪来源的干细胞和晶格。 在一个方面，本发明提供基本上不含脂肪细胞和来自结缔组织干细胞的红血细胞和克隆群体的脂肪来源干细胞。 本发明还提供了从脂肪组织分离干细胞的方法。 细胞可以单独或在生物相容性组合物内使用以在体内和体外产生分化的组织和结构。 此外，细胞可以扩大和培养产生激素，并提供条件培养基来支持其他细胞群的生长和扩增。 另一方面，本发明提供了基本上不含细胞的脂质衍生的晶格，其包含来自脂肪组织的细胞外基质材料。 晶格可以用作底物以促进细胞的生长和分化，无论是在体内还是在体外，进入到原始或甚至成熟的组织或结构中。

公开(公告)号：EP3171902A1

公开(公告)日：2017-05-31

申请号：EP15748200.1

申请日：2015-07-24

Applicant: Müller, Werner Ernst Ludwig Georg

Inventor： Müller, Werner Ernst Ludwig Georg

IPC: A61L27/20 ,  A61L27/46 ,  A61L27/52 ,  A61L27/56 ,  A61L27/58 ,  C08L5/08

CPC classification number: A61L27/46 ,  A61L27/20 ,  A61L27/52 ,  A61L27/56 ,  A61L27/58 ,  A61L2430/02 ,  C08B37/003 ,  C08B37/0084 ,  C08L5/04 ,  C08L5/08 ,  C12N5/0654

Abstract: This invention concerns a formula for the synthesis of a printable hybrid material, formed of carboxymethyl chitosan (CMC) and polyphosphate (polyP). Both polymers are linked together by calcium ions. The inventive CMC-polyP material, in combination with alginate, is biocompatible, biodegradable and useful for three-dimensional (3D) printing and 3D cell printing (bioprinting). The CMC-polyP scaffold, hardened by exposure to calcium ions, is morphogenetically active and can be used in bone N tissue engineering, as a bio mimetic 3-phase scaffold that mimics and induces essential phases in bone repair, including blood clot formation and platelet degranulation (release of growth factors and cytokines) (Phase 1: initiation phase), calcium carbonate bioseed formation (Phase 2: nucleation) and expression/activation of bone alkaline phosphatase (Phase 3: hydroxyapatite-biomineral.

Abstract translation: 本发明涉及由羧甲基壳聚糖（CMC）和多磷酸盐（polyP）形成的可印刷杂化材料的合成配方。 两种聚合物通过钙离子连接在一起。 本发明的CMC-polyP材料与藻酸盐组合是生物相容的，可生物降解的并且可用于三维（3D）印刷和3D细胞印刷（生物印刷）。 通过暴露于钙离子而硬化的CMC-polyP支架具有形态发生活性，可用于骨组织工程，作为模拟和诱导骨修复中必需阶段的仿生性3期支架，包括血块形成和血小板脱粒（ 生长因子和细胞因子的释放）（阶段1：起始阶段），碳酸钙生物体形成（阶段2：成核）和骨碱性磷酸酶的表达/活化（阶段3：羟基磷灰石生物矿物形成）。

公开(公告)号：EP3165601A1

公开(公告)日：2017-05-10

申请号：EP16206687.2

申请日：2005-10-04

Applicant: Universidad Autónoma de Madrid ,  TiGenix, S.A.U.

Inventor： GARCÍA CASTRO, Rosa Ana ,  FERNÁNDEZ MIGUEL, María Gema ,  GARCÍA ARRANZ, Mariano ,  GONZÁLEZ DE LA PEÑA, Manuel Angel ,  GARCÍA OLMO, Damián

IPC: C12N5/074

CPC classification number: A61K35/28 ,  C12N5/0607 ,  C12N5/0619 ,  C12N5/0654 ,  C12N5/0658 ,  C12N5/0667 ,  C12N2506/1384 ,  C12N2510/00 ,  G01N33/5008

Abstract: Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that it is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.

Abstract translation: 从非骨软骨间质组织鉴定和分离多能细胞。 本发明涉及从非骨软骨间充质组织鉴定和分离多能细胞。 具体而言，其涉及从非骨软骨间充质组织分离的成人多能细胞或包含所述细胞的细胞群或组合物，其特征在于其对于以下标记是阳性的：CD9，CD10，CD13，CD29，CD44，CD49A， CD51，CD54，CD55，CD58，CD59，CD90和CD105，并且因为它缺乏以下标记的表达：CD11b，CD14，CD15，CD16，CD31，CD34，CD45，CD49f，CD102，CD104，CD106和CD133。

公开(公告)号：EP2502491B1

公开(公告)日：2017-05-10

申请号：EP12165987.4

申请日：2006-10-31

Applicant: Velico Medical, Inc.

Inventor： Liu, Qiyong Peter ,  Clausen, Henrick

IPC: A01N1/02 ,  C12N9/40 ,  C07K14/78

CPC classification number: C12N5/0654 ,  A61K35/32 ,  A61K35/35 ,  A61L27/3687 ,  A61L27/3695 ,  C12N5/0652 ,  C12N9/2465 ,  C12N2501/73 ,  C12N2506/09 ,  C12N2506/13 ,  C12N2506/1315 ,  C12N2506/14 ,  C12N2506/25 ,  C12Y302/01022